Breaking AI & Tech News Analyzed

Al-Noor Centre has become a vital source of hope for blind children living in the besieged Gaza Strip. In a region where basic infrastructure is strained, the centre offers specialized education, mobility training, and psychosocial assistance that enable young patients to navigate daily challenges. By delivering tailored services, the centre not only addresses the immediate needs of its beneficiaries but also underscores the broader importance of disability‑focused humanitarian aid in conflict zones. Such initiatives help mitigate long‑term social exclusion and foster greater community resilience. Stakeholders and donors recognize that supporting facilities like Al-Noor is essential for safeguarding the rights of children with disabilities, especially amid ongoing security and economic pressures. The centre’s work illustrates how targeted interventions can serve as a lifeline, offering both practical assistance and a sense of dignity to a vulnerable population. As Gaza continues to grapple with humanitarian challenges, the sustained operation of the Al-Noor centre stands as a testament to the impact of focused aid programs that prioritize the most marginalized groups.

Thousands of Iranians who had fled Tehran during the recent war have begun returning to their homes or workplaces, despite the fragile truce and looming anxiety over the approaching ceasefire deadline.Mehdi, a 36-year-old IT professional, is one of them. He had fled to the north with relatives in the early days of the war, but has now returned to find his home damaged by blasts, with shattered glass and blown-out bedroom window frames.The city is riddled with ruined buildings, destroyed infrastructure, and an economy in turmoil. Mehdi describes the experience of hearing missiles hit nearby: 'There's a whistling sound I hope you never hear … a missile so close that you don't know if it's going to hit your house or your neighbour's.'Many residents, especially those reliant on the internet, have lost their livelihoods due to the 45-day internet blackout imposed by Iranian authorities. This has left most of Iran's population cut off from the world, with some paying large sums to access the internet through Starlink and VPNs.Noor, an activist based in Tehran, says 10 million Iranians depend on internet access to run small businesses or make an income. The economic pressure has become unbearable, with food items and medications for patients with serious or chronic illnesses becoming difficult to find or afford.The economic crisis has worsened, with factories struggling to operate due to a lack of raw materials, construction workers losing jobs, and workplaces laying off staff or reducing their workforce.

Israel has escalated its attacks on medical workers in Lebanon, with a recent 'quadruple tap' killing four medics and wounding six others. The attacks, which have been condemned by the Lebanese health ministry and the World Health Organization, have left healthcare workers in Lebanon feeling vulnerable and under attack.The 'quadruple tap' occurred when Israeli forces targeted an initial airstrike site, then hit the ambulances and medical workers who responded to the scene, and finally struck again twice more. This tactic has been criticized as a blatant violation of international humanitarian law, which protects medical workers and facilities.The Lebanese health ministry has accused Israel of deliberately targeting ambulance crews, stating that 'paramedics have become direct targets, pursued relentlessly in a blatant violation that confirms a total disregard for all norms and principles established by international humanitarian law.'The attacks have resulted in the deaths of 91 healthcare workers and the wounding of 214 others in Lebanon since the Israel-Hezbollah war started on March 2. The World Health Organization has called for the immediate protection of healthcare facilities, health workers, ambulances, and patients.The Israeli military has not provided justification for its repeated attacks on medical infrastructure and workers, apart from accusing Hezbollah of using ambulances and hospitals to transport fighters and weapons, without providing evidence for the claim.

Aaron Pierre delivers a storming, almost hypnotic performance as Randle P. McMurphy, instantly igniting the stale atmosphere of a 1960s American psychiatric ward. His swagger‑filled stride and sudden, childlike scampers create a compelling contrast that keeps the audience on edge.From the opening moments, McMurphy clashes with the authoritarian Nurse Ratched (Olivia Williams), provoking the other patients to rebel, play, and celebrate life beyond the ward’s walls. Pierre’s physicality—alternating between boisterous hugs and a frantic, vulnerable laugh—captures the character’s chaotic charisma.Director Clint Dyer, fresh from his acclaimed 2022 Othello, reshapes the narrative by casting the inmates almost entirely with Black actors. This choice injects a fresh political dimension, turning the patients into “pawns in a system designed to disempower.” Each time Ratched addresses them as “boys,” the line feels like an implicit sneer.While the script does not overtly discuss race—apart from Chief Bromden’s (Arthur Boan) Indigenous background—the production foregrounds the systemic misogyny embedded in both the novel and the 1963 Dale Wasserman adaptation. McMurphy’s mantra, “I fight and fuck,” teeters between liberated individualism and a problematic reclamation of alpha‑male tropes.Olivia Williams, who stepped into the role of Nurse Ratched late in rehearsals, gives the character a “ramrod spine and starched smile.” Her performance underscores the unchecked cruelty of a regime where the doctor (Matthew Steer) is a peripheral, snickering figure, leaving Ratched’s authority unchecked and increasingly vicious.Ken Kesey’s own experience as a government‑run LSD guinea‑pig informs the play’s visceral critique of psychiatry. The production’s lighting, designed by Chris Davey, erupts in scarlet and blue hues that echo the anti‑psychiatry movement of the 1960s, while the depiction of medication, group therapy, and electroconvulsive therapy feels deliberately brutal.Staged in the round at the Old Vic, the audience becomes a “ring of often appalled observers.” Ben Stone’s set design, with its white and pond‑green tiles beneath a soaring ceiling, creates a claustrophobic floor that simultaneously aspires upward—mirroring the characters’ yearning for freedom.The ensemble, led by Giles Terera’s refined Dale Harding, adds subtle layers of tension through nuanced tics and gestures. Dyer bookends the show with a reference to Congo Square in New Orleans, a historic site of Black and Indigenous resistance, framing the play’s cruelty through a lens of cultural resilience—though the production remains largely filtered through a male gaze.The production runs at the Old Vic until 23 May 2026, offering London audiences a bold, politically charged reinterpretation of a classic American drama.

A recent Cochrane review analyzing 17 clinical trials involving over 20,000 people with mild cognitive impairment or dementia has concluded that anti-amyloid drugs have a 'trivial' effect on cognition and dementia severity over 18 months.The review, which assessed seven anti-amyloid drugs, found that improvements in functional ability were 'small at best' and that the drugs caused more swelling and bleeding in the brain than the placebo.The findings are a blow to the new wave of drugs designed to slow Alzheimer's by clearing clumps of amyloid protein that build up in the brain. Despite initial hype, with some regulators approving drugs like lcanemab and donanemab, many countries have stopped short of providing them through public health services due to concerns over their effectiveness and cost.Critics of the review argue that it combines results from older, failed drugs with those from newer, more effective medicines, which may skew the conclusions. However, the review's authors defend their approach, stating that all the drugs aimed to remove amyloid from the brain and assessed the impact on patients in a similar way.The review's lead author, Edo Richard, notes that the effect sizes are too small for patients and caregivers to notice, and that the drugs are also 'burdensome' due to the need for regular intravenous drug infusions and MRI scans.Experts in the field, such as Robert Howard, express concerns that the drugs may not truly alter the course of Alzheimer's, and that it's unfair to raise expectations in patients. Meanwhile, Alzheimer's Research UK argues that the review's conclusions are limited by its methodology and that anti-amyloid treatments will not be the whole answer to curing Alzheimer's.

On O’Connell Street, a lime‑green CLAAS tractor arrived with a 19‑year‑old driver named Dylan, who explained that his convoy was the second to join a city‑wide fuel blockade that halted traffic for nearly a week. The protest, organized by farmers, hauliers and fishermen, highlighted the impact of a 60% increase in fuel duties and taxes on everyday Irish life. Dylan warned that the surge in fuel costs would eventually ripple through food prices, threatening household budgets across the nation. He and his companions, two teenagers, had endured cold nights inside the tractor, underscoring the desperation felt by many workers. The unrest, described by the Irish president as an "illegal war on Iran," has laid bare Ireland’s dependence on fossil fuels and the lack of a coherent transition strategy toward renewable energy. During six days of action, protestors blocked motorways, ports, the country’s sole oil refinery in County Cork, and fuel depots in Limerick and Galway. By the end of the week, petrol stations began to run low, prompting the justice minister to consider deploying the army. Yet on the streets, public sentiment was largely supportive; a recent poll indicated that 56% of respondents backed the demonstrators. Historical symbolism filled the scene: tractors flew the Irish tricolour beside buildings still scarred by the 1916 Easter Rising, while a lorry bore a painted coffin with the words "RIP Ireland" and a banner reading "Easter 2026". Critics on national radio questioned the tactics, citing concerns for vulnerable patients unable to reach medical appointments. Nonetheless, the direct‑action approach succeeded in drawing international attention and pressuring the government. When mounted police units arrived on Sunday morning, the convoy withdrew peacefully. Shortly thereafter, the coalition of Fianna Fáil and Fine Gael announced a €500 million concession package, augmenting an earlier €250 million relief plan with cuts to excise duty and a postponement of the next carbon‑tax increase. Despite the financial concessions, a looming no‑confidence vote appears unlikely to topple the centre‑right coalition, even as public trust in traditional parties wanes. Dylan, too young to have voted in the last election, expressed little confidence in the political establishment. The protests have also been infiltrated by far‑right elements, with some speakers promoting anti‑immigrant conspiracies and misogynistic rhetoric. One spokesperson was found to have prior convictions for animal cruelty, and the Muslim Sisters of Éire reported being told to "go home" by flag‑waving agitators, highlighting a surge in xenophobic discourse. Beyond the immediate fuel price surge—up roughly 20% in a single month—the demonstrations raise broader questions about Ireland’s reliance on volatile global markets. The nation imports over 80% of its fruit and vegetables, while its data‑centre sector now consumes more electricity than all urban households combined, underscoring the tension between economic growth and sustainable energy policy. Analysts argue that lasting change cannot be achieved by pushing working people to the brink while catering to corporate interests. Ireland is expected to lobby the EU for a pause on carbon‑tax increases and to join calls for an EU‑wide tax on oil and gas profits, similar to measures advocated by Spain. In sum, the Dublin fuel blockade has forced the government to concede significant fiscal relief, exposed deep structural vulnerabilities in Ireland’s energy and food supply chains, and sparked a contentious debate over the role of grassroots protest, social cohesion, and climate justice.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”